DHILLON PUNIT 4

What Happened
Skye Bioscience CEO Punit Dhillon was the subject of a board-approved one‑time repricing on March 31, 2026. The Form 4 shows matched derivative transactions: dispositions of previously issued options back to the issuer and concurrent grants of new options. Total amounts: 1,103,959 option shares were cancelled (dispositions to issuer) and 1,103,959 option shares were re‑granted. The repriced options carry an exercise price of $0.615 per share (the issuer’s closing price on the repricing date). These are derivative transactions (options), not open‑market stock buys or sales.

Key Details

• Transaction date: March 31, 2026; Form 4 filed April 2, 2026 (timely).
• Aggregate re‑granted option shares: 1,103,959; same aggregate amount disposed/cancelled.
• Repriced exercise price: $0.615 per share (per footnote F1).
• Transaction type: Derivative grant (A) and disposition to issuer (D) — old options canceled and new options issued.
• Vesting/other notes: Some options are fully vested (F2); other grants vest monthly over four years beginning on various grant dates (see F4–F7). All referenced options accelerate to 100% vesting on a change of control.
• Shares owned after transaction: Not reported in the provided excerpt.
• No cash sale or market transaction reported — this is an issuer‑approved repricing/regrant, not a purchase or sale by the CEO.

Context
For retail investors: this is an internal compensation adjustment (repricing/regrant of options) rather than a purchase (bullish signal) or open‑market sale (potentially bearish or routine). The board approved the single‑day repricing; the exercise price equals the market close on that date. Vesting schedules and change‑of‑control acceleration are noted in the footnotes, which may affect future timing of any exercises or sales.